184 related articles for article (PubMed ID: 36112541)
1. FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Duke ES; Stapleford L; Drezner N; Amatya AK; Mishra-Kalyani PS; Shen YL; Maxfield K; Zirkelbach JF; Bi Y; Liu J; Zhang X; Wang H; Yang Y; Zheng N; Reece K; Wearne E; Glen JJ; Ojofeitimi I; Scepura B; Nair A; Bikkavilli RK; Ghosh S; Philip R; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2023 Feb; 29(3):508-512. PubMed ID: 36112541
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Chon K; Larkins E; Chatterjee S; Mishra-Kalyani PS; Aungst S; Wearne E; Subramaniam S; Li Y; Liu J; Sun J; Charlab R; Zhao H; Saritas-Yildirim B; Bikkavilli RK; Ghosh S; Philip R; Beaver JA; Singh H
Clin Cancer Res; 2023 Sep; 29(17):3262-3266. PubMed ID: 37022784
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
4. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
5. Mobocertinib: Mechanism of action, clinical, and translational science.
Hanley MJ; Camidge DR; Fram RJ; Gupta N
Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Zhou C; Ramalingam SS; Kim TM; Kim SW; Yang JC; Riely GJ; Mekhail T; Nguyen D; Garcia Campelo MR; Felip E; Vincent S; Jin S; Griffin C; Bunn V; Lin J; Lin HM; Mehta M; Jänne PA
JAMA Oncol; 2021 Dec; 7(12):e214761. PubMed ID: 34647988
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
[TBL] [Abstract][Full Text] [Related]
9. Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Huang WS; Li F; Gong Y; Zhang Y; Youngsaye W; Xu Y; Zhu X; Greenfield MT; Kohlmann A; Taslimi PM; Toms A; Zech SG; Zhou T; Das B; Jang HG; Tugnait M; Ye YE; Gonzalvez F; Baker TE; Nadworny S; Ning Y; Wardwell SD; Zhang S; Gould AE; Hu Y; Lane W; Skene RJ; Zou H; Clackson T; Narasimhan NI; Rivera VM; Dalgarno DC; Shakespeare WC
Bioorg Med Chem Lett; 2023 Jan; 80():129084. PubMed ID: 36423823
[TBL] [Abstract][Full Text] [Related]
10. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Christopoulos P; Prawitz T; Hong JL; Lin HM; Hernandez L; Jin S; Tan M; Proskorovsky I; Lin J; Zhang P; Patel JD; Ou SI; Thomas M; Stenzinger A
Lung Cancer; 2023 May; 179():107191. PubMed ID: 37058788
[TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Khozin S; Blumenthal GM; Jiang X; He K; Boyd K; Murgo A; Justice R; Keegan P; Pazdur R
Oncologist; 2014 Jul; 19(7):774-9. PubMed ID: 24868098
[TBL] [Abstract][Full Text] [Related]
12. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
Brazel D; Kroening G; Nagasaka M
BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
[TBL] [Abstract][Full Text] [Related]
13. New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
David GM; Maria Del Pilar BC; Cristina MR
J Oncol Pharm Pract; 2023 Jun; 29(4):934-943. PubMed ID: 36916182
[TBL] [Abstract][Full Text] [Related]
14. Mobocertinib: First Approval.
Markham A
Drugs; 2021 Nov; 81(17):2069-2074. PubMed ID: 34716908
[TBL] [Abstract][Full Text] [Related]
15. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
Riely GJ; Neal JW; Camidge DR; Spira AI; Piotrowska Z; Costa DB; Tsao AS; Patel JD; Gadgeel SM; Bazhenova L; Zhu VW; West HL; Mekhail T; Gentzler RD; Nguyen D; Vincent S; Zhang S; Lin J; Bunn V; Jin S; Li S; Jänne PA
Cancer Discov; 2021 Jul; 11(7):1688-1699. PubMed ID: 33632775
[TBL] [Abstract][Full Text] [Related]
16. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for
Yang JC; Zhou C; Jänne PA; Ramalingam SS; Kim TM; Riely GJ; Spira AI; Piotrowska Z; Mekhail T; Garcia Campelo MR; Felip E; Bazhenova L; Jin S; Kaur M; Diderichsen PM; Gupta N; Bunn V; Lin J; N Churchill E; Mehta M; Nguyen D
Expert Rev Anticancer Ther; 2023 Jan; 23(1):95-106. PubMed ID: 36537204
[TBL] [Abstract][Full Text] [Related]
17. Mobocertinib in non-small cell lung cancer.
Liu S; Lowder KE
Drugs Today (Barc); 2022 Nov; 58(11):523-530. PubMed ID: 36422513
[TBL] [Abstract][Full Text] [Related]
18. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
19. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Prelaj A; Bottiglieri A; Proto C; Lo Russo G; Signorelli D; Ferrara R; Galli G; De Toma A; Viscardi G; Brambilla M; Lobefaro R; Nichetti F; Manglaviti S; Occhipinti M; Labianca A; Ganzinelli M; Gallucci R; Zilembo N; Greco GF; Torri V; de Braud F; Garassino MC
Eur J Cancer; 2021 May; 149():235-248. PubMed ID: 33820681
[TBL] [Abstract][Full Text] [Related]
20. Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.
Gupta N; Largajolli A; Witjes H; Diderichsen PM; Zhang S; Hanley MJ; Lin J; Mehta M
Clin Pharmacol Ther; 2022 Aug; 112(2):327-334. PubMed ID: 35467009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]